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Background: The immune system and vascular endothelial growth factor (VEGF) may be influential in melanoma
behavior. We performed a prospective, exploratory analysis in 10 stage III and 22 stage IV melanoma patients to
observe factors influencing outcomes.
Patients and methods: Patients accrued during 2010 and 2011 were treated according to standard protocols for
disease stage. We analyzed selected biomarkers for predictive patterns of clinical response. Survival outcomes were
calculated using Kaplan-Meier curves.
Results: Baseline LDH was negatively correlated with length of survival and positively correlated to baseline VEGF in
stage IV melanoma patients. We found a positive correlation between peripheral blood Treg concentrations and baseline
VEGF in stage IV patients. No stage III patients died during the study period; median survival for stage IV patients was
48 months using a Kaplan-Meier survival curve, which illustrates the enrichment for exceptional stage IV survivors. Six
stage IV patients remain disease free, including 4 of the 10 patients who received IL-2 +/− metastatectomy.
Conclusions: Recent advances in immunotherapy have demonstrated durable therapeutic responses which may
favorably impact survival. Examining T-cell characteristics of metastatic melanoma patients may gain further insight into
underlying immunomodulation mechanisms to guide improved therapies.
Keywords: Melanoma; Stage IV; Biomarkers; VEGF; Tregs; TH1/TH2 ratio; CD4+/CD8+ ratio; LDHIntroduction
As the incidence of cutaneous melanoma has risen in-
crementally in the United States, it has become a focus
of public health concern. In 2014, an estimated 76,100
persons will be diagnosed with melanoma with 9,710 es-
timated deaths (American Cancer Society. Cancer Facts
and Figures 2014). Survival rates are largely dependent
on the stage of disease at initial diagnosis. Prior to 2011,
treatment options have been limited and, overall, disap-
pointing for stage IV melanoma. High-dose interleukin-
2 (IL-2) as well as traditional chemotherapies comprised
the mainstay of treatment. A new paradigm for primary* Correspondence: suresh.nair@lvhn.org
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in any medium, provided the original work is psystemic treatment for metastatic melanoma has shifted
toward immunotherapy including IL-2, anti-CTLA4
monoclonal antibody (ipilimumab), and programmed
cell death 1 antibody (anti-PD1), as well as targeted ther-
apies (BRAF or MEK inhibition). As the preferred se-
quence of treatment in metastatic melanoma is yet
undefined, it becomes important to delineate prognosti-
cators of response with selected treatments.
High-dose IL-2 is associated with prolonged survival in
selected individuals and is a potentially curative therapy in
metastatic melanoma; hence, it deserves special consider-
ation. In the metastatic setting, complete response rates ap-
proach 6% with partial response rates of approximately 10%
(Atkins et al. 1999). Prior to initiation of therapy, there is
currently no way to select patients who will favorably re-
spond. Moreover, despite its durable efficacy, IL-2 induces
a marked pro-inflammatory cascade responsible for itss an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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the systemic capillary leak syndrome. In an effort to bet-
ter define characteristics of patients who may benefit
from IL-2 therapy, Phan and colleagues (Phan et al.
2001) retrospectively reviewed their experience of 374
patients with stage IV melanoma who were treated with
high-dose IL-2 from 1988 – 1999. Metastatic subset of
disease was influential on response rates (RR), with cuta-
neous or subcutaneous metastatic disease having a RR of
53.6% compared to 12.4% for other sites of metastatic
disease. A negative trend was noted for intracranial me-
tastases. Other factors significantly related to response
included post-treatment lymphocytosis and immunologic
toxicity, such as vitiligo. Using gene microarray profiling,
Sabatino and colleagues (Sabatino et al. 2009) identified
that pre-treatment levels of vascular endothelial growth
factor (VEGF) was an independent predictor of clinical
response in IL-2 treated patients. They further defined
that patients with VEGF levels >125 pg/mL exhibit sig-
nificantly reduced overall survival (OS) (13 versus
23.3 months; p < 0.007) than patients below this cutoff.
Angiogenesis inhibition by targeting VEGF in combin-
ation with chemotherapy has been investigated in meta-
static melanoma. High plasma VEGF levels have been
associated with poor clinical outcomes in the setting of
metastatic melanoma (Brychtova et al. 2008). The North
Central Cancer Treatment Group conducted a phase 2
trial combining carboplatin, weekly paclitaxel, and bi-
weekly bevacizumab in stage IV melanoma (Perez et al.
2009). Partial remission was achieved in 9 (17%) of the
patients and stable disease achieved for at least 8 weeks
in 30 (57%) of the patients. Median progression-free
survival (PFS) and median OS were 6 months and
12 months, respectively. Plasma VEGF-A levels (the
most common isoform) were measured pretreatment
and at 4 weeks. There was no association between
VEGF-A levels and PFS (Perez et al. 2009). Additionally,
serum lactate dehydrogenase (LDH) is a well-recognized
independent prognostic indicator for survival in patients
with metastatic melanoma (Sirott et al. 1993, Agarwala
et al. 2009, Abeloff et al. 2008) and is a surrogate marker
for disease progression in stage IV disease (Agarwala
et al. 2009).
Immunotherapies have emerged as an area of active
focus in melanoma research. The immune system pro-
duces various CD4+ T-cell responses including Th1 and
Th2. A distinct subset of CD4+ T-cells were identified in
2005 called Th17. These T helper cells regulate host
defense and may have a role in tumor immunity (Paulos
et al. 2014). We limited our analyses to the Th1 and Th2
subsets. The Th1 response is characterized by a domin-
ance of the cytokine interferon-γ, which stimulates CD8+
cytotoxic T-lymphocytes that have an antineoplastic effect.
Th2 responses are dominated by the cytokine interleukin-4(IL-4) and are thought to be pro-neoplastic and nurture a
chronic inflammatory state (Abeloff et al. 2008; Jiang &
Chess 2006). Chronic inflammation has been linked to the
progression of melanoma at the level of the tumor micro-
environment with associated immune dysregulation
(Nevala et al. 2009).
Hernberg and colleagues (Hernberg et al. 2004) ob-
served that an early increase in CD4+/CD8+ ratio in
metastatic melanoma patients during treatment was a fa-
vorable prognostic indicator. In Hernberg’s study, pa-
tients who had decreasing levels of CD8+ T-cells had a
median survival of 27.8 months; whereas, patients with
increasing levels had a median survival of 10.8 months.
Cytokine-secreting regulatory T-cells (Tregs) mediate
regulatory function of immune response and can shift
immune system balance toward Th1 or Th2 dominant
state (Jiang & Chess 2006). IL-2 is a T-cell growth factor
and mediates Treg expansion in vivo, favoring a Th2-
dominated state, which may account for patterns of
failure with IL-2 therapy. It has been suggested that se-
lective inhibition of IL-2-mediated enhancement of Tregs
may improve therapeutic efficacy of IL-2 (Ahmadzadeh &
Rosenberg 2006). Nevala and colleagues (Nevala et al.
2009) demonstrated that malignant melanocytes highly
up-regulate VEGF transcripts as measured by plasma
VEGF concentrations and perpetuate a chronically Th2-
mediated state.
Our study was a hypothesis-generating, prospective
evaluation of the role of VEGF and selected immune-
modulatory cells including Treg, Th1/Th2 ratio and
CD4+/CD8+ ratio, as well as BRAF status and baseline
LDH in stage III and IV melanoma patients undergoing
active treatment. Our goal was to observe trends that
may help guide initial choice of therapy in advanced
melanoma or reveal immunomodulary patterns. After an
extensive review of the literature, we found no studies
on the correlation among LDH, Tregs, VEGF or Th1/
Th2 ratio in relation to each other.
Patients and methods
Patients and treatment
We prospectively gathered data and collected blood
samples via venopuncture from 10 stage III and 22 stage
IV patients referred to our institution for the treatment
of melanoma. At study enrollment, we collected 90 mls
of blood as drawn into acid citrate dextrose vacutainers
and PBMCs were isolated using a Ficoll gradient. Plasma
was also collected prior to the ficoll gradient and stored
at −80°C in 1 ml aliquots. Isolated PBMCs were washed
with 1x PBS and suspended in freezing media (90% Cos-
mic Calf serum and 10% DMSO). PBMCs were stored
and batch analyzed by flow cytometer. Patient character-
istics are described in Table 1. Prior therapies are listed
in Table 2. The Lehigh Valley Health Network








Age (Mean ± SD) 56.44 ± 10.52 55.77 ± 11.10 57.90 ± 9.72
Males N (%) 22 (68.8) 15 (68.2) 7 (70.0)
Stage IV Sub-type N (%)
IVa - 2 (9.1) -
IVb - 3 (13.6) -
IVc - 17 (77.3) -
BRAF
Mutated 11 (34.4) 7 (31.8) 4 (40)
Wild Type 16 (50) 14 (63.6) 2 (20)
Not Available 5 (15.6) 1 (4.5) 4 (40)
Length of follow-up in
months (Mean ± SD)
39.28 ± 21.86 36.32 ± 24.63 45.80 ± 12.73
BRAF, B-type Raf kinase; SD, standard deviation.
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crual of any study participants. All study participants
provided written informed consent. The patients were
treated according to standard protocols for disease stage
including resection and interferon or observation for
stage III patients and resection +/− GM-CSF, IL-2,
ipilimumab, vemurafenib, carboplatin/paclitaxel/bevacizu-
mab and temozolomide for stage IV patients. Original bi-
opsy specimens were sent for BRAF mutational analysis.
Some patients received treatments for melanoma prior to
enrollment.
Subject inclusion criteria included age >18 years old,
histological confirmation of stage III or IV melanoma asTable 2 Treatments for stage III and stage IV patients
















Chemo – chemotherapy, Targeted – targeted therapy, Immunotherapies
include: High-dose Interleukin-2, Ipilimumab, granulocyte macrophage
colony-stimulating factor, and interferon; Chemotherapies include: carboplatin,
paclitaxel, paclitaxel nanoparticle albumin-bound, and temozolomide;
Targeted therapies include: vemurafenib; Anti-angiogenic agents include:
thalidomide, bevacizumab.defined by the AJCC Staging Handbook (Edge et al.
2010), ability to provide informed consent, and willing-
ness to participate. Exclusion criteria included condi-
tions associated with VEGF level elevations such as
chronic non-healing wounds, uncontrolled hypertension
defined as blood pressure >140/90 on 3 separate mea-
surements on 3 separate days, and uncontrolled on anti-
hypertensive therapy; uncontrolled inflammatory state
(connective tissue disease, inflammatory bowel disease,
chronic infections, or active, second malignancy); and
pregnancy.
All serum samples were prospectively collected and in-
cluded baseline LDH and baseline VEGF levels with
VEGF-A isoform (Table 3). The VEGF-A ELISA was per-
formed at room temperature per procedural guidelines
of R & D systems (R & D Systems, Minneapolis, MN).
The plate was read at 450 nm and 540 nm on a lumines-
cence microplate reader. The wavelength correction was
done by subtracting the reading of 540 nm from that of
450 nm. Lactate dehydrogenase levels were assayed in a
commercial laboratory (Health Network Labs, Allentown,
PA) on a Siemen’s Dimension Vista 500 (Siemens Medical
Solutions, Malvern, PA). Substrate L-lactate was buffered
at a pH of 9.4 and lactate dehydrogenase was added to
that substrate to yield pyruvate and NADH. This absorbs
light at 340 nm allowing rate reaction measurement.
BRAF V600E testing was performed by Clarient laborator-
ies (Clarient Inc, Aliso Viejo, CA) by allele-specific poly-
merase chain reaction.
Baseline direct measurements of Th1 and Th2 were
performed by flow cytometry. Cellular phenotypes were
determined using multiparametric flow cytometry. The
antibodies used are as follows: FITC anti-human CD294
and PE anti-human TIM-3 (R & D Systems, Minneapolis,
MN), FITC anti-human CD3, PC5 anti-human CD4 and
PC7 anti-human CD8, FITC anti-human CD16, PE anti-
human CD56, PC5 anti-human CD3, FITC anti-human
CD69, PE anti-huamn CD62L, FITC anti-human CD14,
PC5 anti-human CD11c, PE anti-human HLA-DR, PC7
anti-human CD80, PC7 anti-human CD83, PC7 anti-
human CD86, PC7 anti-human CD123, PE anti-CD40,
FITC anti-human CD25, and PE anti-human CD304
(neuropilin-1 receptor) (BD Pharmingen, Piscataway,
NJ) Previously viably frozen cells were thawed and
stained with surface antibodies for 30 minutes at 4°C in
FACS buffer (PBS with 0.5% BSA and 0.05% Sodium
Azide). After incubation all cells were washed twice in
FACS buffer and suspended in 4% paraformaldehyde in
PBS and data was collected on a Gauva 8HT flow cyt-
ometer Millipore Billerica, MA) and; data analysis was
performed using FlowJo software (FlowJo Ashland, OR).
T-helper 1 cells were defined as CD4+ and TIM3+ while
T-helper 2 cells were CD4+ and CD294+. Our gating
strategies using Tim3+ to define Th1 and CD294+ to







LDH U/L (Median, Q1, Q3) 223.50, 199.25, 263.75 230.00, 211.50, 307.50 200.00, 171.50, 245.50
VEGF pg/mL (Mean ± SD) 400.40 ± 252.88 422.69 ± 294.45 351.37 ± 118.71
Treg % (Mean ± SD) 27.13 ± 6.15 27.56 ± 6.43 26.18 ± 5.68
Th1/Th2 (Mean ± SD) 0.62 ± 0.17 0.64 ± 0.15 0.58 ± 0.20
CD4/CD8 (Median, Q1, Q3) 1.70, 1.22, 2.14 1.76, 1.01, 2.19 1.65, 1.32, 2.05
LDH, lactic acid dehydrogenase; Q1, first quartile; Q3, third quartile; VEGF, vascular endothelial growth factor; SD, standard deviation; Treg, regulatory T cell.
Table 2: Q1 = first quartile, Q3 = third quartile, SD – standard deviation.
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et al. 2011; Monney et al. 2001). Lee et al. (2011) have de-
scribed the same CD4+/CD294+ gating strategy we used
in our study. Monney et al. (2001) have characterized
Tim-3 expression on Th1 cells. The percentages are of the
live-gated cells on forward and side scatter dot plots. The
Th1:Th2 ratios were calculated by dividing the percentage
of Th1 positive cells by the percentage of Th2 positive
cells (Table 3). In this study Treg cells were defined as
CD4+, CD25+ and CD304+ triple positive cells. The per-
centage of cells was determined from CD4+ cells from the
live gate. From the CD4+ gate, the percentage of CD25+
and CD304+ cells were determined. Although neuropilin-
1 has been identified as a specific marker of murine Treg
its applicability as a marker of human Treg has been ques-
tioned (Milpied et al. 2009). However, CD304+ has been
previously described as a marker for Tregs by others
(Battaglia et al. 2010; Piechnik et al. 2013). Examples of
gating strategies (Figures 1a, 1b, and 1c) and isotype
controls (Figure 1d) are presented in Figure 1.
Statistical analyses
This study involved a convenience sample of 32 mel-
anoma patients seen at our institution between 2010
and 2011. We assessed the correlation between VEGF,
several immune-modulatory cells and cytokines, BRAF
status, baseline LDH, survival, and length of survival.
Pearson’s Correlation Coefficient (r) was used when
both variables were continuous and normally distrib-
uted. Spearman’s Rank Correlation Coefficient (rs) was
used if both variables were continuous and one or
both were not normally distributed. The Point-Biserial
Correlation Coefficient (rpb) was reported if one of the
variables was dichotomous and the other was numeric.
The Phi Coefficient was reported if both of the vari-
ables were dichotomous (Warner 2008). The criteria set
forth by Cohen (1988) were used to interpret the correl-
ation coefficients. A correlation coefficient of 0.1 is consid-
ered “small”, 0.3 is considered “medium”, and 0.5 is
considered “large”. Normality of the variables was deter-
mined using the skewness statistic as well as the Shapiro-
Wilk Test, as this test is appropriate for sample sizes <50
(Lund Research Ltd. 2013). Kaplan-Meier Curves weregenerated to illustrate median survival in stage IV patients
with low baseline LDH (defined as <250) compared to
those with high baseline LDH (defined as > =250). A Cox
Proportional Hazards Regression model was used to assess
whether or not any of the variables that were found to be
correlated with survival were also predictive of survival.
Data was analyzed separately for stage III and IV pa-
tients. The analysis was conducted using IBM® SPSS®
Statistics version 22.0 and MedCalc® version 12.4.0.0. All
tests were two-tailed. Alpha was set at 0.05.
Results
There were 22 stage IV and 10 stage III melanoma pa-
tients included in this study. The mean length of follow-
up was 45.80 (±12.73) months for stage III patients and
36.32 (±24.63) months for stage IV patients (Table 1). At
study completion, none (0.0%) of the stage III patients
and 13 (59.1%) of the stage IV patients had expired.
In stage IV patients, we found a medium, positive correl-
ation (r = .485, n = 22, p = .022) between Treg levels and
baseline VEGF (Figure 2a), and a large, positive correlation
(rs = .697, n = 21, p < .001) between baseline LDH and
VEGF (Figure 2b). There was a medium, negative correl-
ation (rs = −.495, n = 21, p = .022) between baseline LDH
and length of survival. Median survival for stage IV patients
was 48 months. Median survival could not be calculated for
stage III patients, who were all still alive at study comple-
tion. Median survival for stage IV patients with low baseline
LDH and those with high baseline LDH was 59 months
and 10 months, respectively (Figure 3). Baseline LDH
was found to be predictive of survival in stage IV patients
(HR = 1.0017, 95% CI: 1.0003 – 1.0032, p = 0.0214).
Discussion
The landscape of metastatic melanoma treatment has
evolved strikingly in recent years with the develop-
ment of antitumor molecular targets, including BRAF-
inhibitors such as vemurafinib and dabrafenib (Flaherty
et al. 2010a) and MEK-inhibition with trametinib (Flaherty
et al. 2010b). Ipilimumab, a fully human monoclonal anti-
body has been shown to block cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4), an immune checkpoint
molecule that down-regulates pathways of T-cell activation
Figure 1 Scatterplots of Gating Analyses for CD4+, CD8+, Th1, Th2 and Treg with isotype controls, (1a) - CD4+ and CD8+, (1b) - Th1 (CD4+ and
TIM3+), Th2 (CD4+ and CD294+), (1c) - Treg (CD4+, CD25+, and CD304+), (1d) -Isotype Controls.
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antibodies directed against the programmed death 1
(PD-1) checkpoint molecule (Topalian et al. 2012) or
its ligand (PDL-1) (Brahmer et al. 2012). Each drug has
a unique mechanism of action and newer therapies have a
substantial financial burden. As oncology practice is evolv-
ing into a personalized-medicine treatment approach, it
becomes important to define variables and patient charac-
teristics in advanced disease that may be predictive of
treatment response, or aid in selection of the patients
most likely to benefit as well as in selection of optimal
treatments.
Angiogenesis, the formation and differentiation of
blood vessels, is fundamental in neoplastic growth andmetastatic dissemination (Folkman 1995). VEGF has
been recognized as an important regulator of pathologic
angiogenesis and is associated with tumor progression
and poor outcomes in a variety of human cancers includ-
ing metastatic melanoma (Brychtova et al. 2008; Salven
et al. 1997; Gasparini et al. 1997). Measurement of serum
VEGF has been utilized as a surrogate marker of tumor
angiogenesis (Kraft et al. 1999) and as a predictive bio-
marker for prognosis and therapeutic response (Sabatino
et al. 2009). Disruption in immune homeostasis with a
shift toward a Th2-dominant or chronic inflammatory
state by tumor-derived VEGF has been previously re-
ported. It is this ‘reprogramming’ of systemic immunity
that may be permissive to tumorigenesis and metastatic
Figure 2 Scatter Plots of Correlation. a between Baseline VEGF and Baseline Treg in Stage IV Patients b between Baseline VEGF and Baseline LDH
in Stage IV Patients.
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munosuppression in conjunction with angiogenesis is ac-
tive in metastatic melanoma.
We formulated a hypothesis-generating pilot study
utilizing a practical means of measuring levels of im-
munosuppression and angiogenesis in melanoma. We
examined the relationship between VEGF and bio-
markers of immune function, including Tregs, Th1/Th2
ratio and CD4+/CD8+ ratio, in a prospective cohort of
patients. Our observations may be useful as a basis for
planning of larger trials in the future. To our knowledge,
we observed for the first time a positive relationship be-
tween baseline VEGF and Tregs as well as a positivecorrelation between baseline VEGF and LDH in stage IV
patients. We found no association between baseline
VEGF, BRAF status and CD4+/CD8+ ratio with sur-
vival. We sought to examine the impact of baseline
measurable markers of immune status on survival in
stage IV melanoma patients treated aggressively at a
high-dose IL-2 center during the time period of 2010
and later. Our general treatment philosophy for stage
IV disease was immunotherapy as first-line, followed
by targeted therapy and chemotherapy as later options.
This is aligned with the 2013 Society for Immuno-
therapy of Cancer consensus statement (Kaufman et al.
2013).
Figure 3 Survival Curves for Stage IV Patients Based on LDH.
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activation (measured by serum VEGF) and possible de-
velopment of immune tolerance (measured by Treg fre-
quency). Regulatory T cells (T regs) influence antitumor
responses by their potent immunosuppressive function.
High concentrations of T regs within tumors as well as
peripheral blood in various cancer subtypes have been
linked to poorer prognosis (Nishikawa & Sakaguchi
2010). Their relationship to VEGF continues to be inves-
tigated particularly the relationship within tumor tissue
(tumor infiltration). VEGF has been studied as a promoter
of Treg activation in antitumor immunity. Currently, it is
favored that immune evasion is more correlated with ex-
pansion of Tregs within the tumor microenvironment ra-
ther than in the peripheral blood. In a murine in vitro
model, Hansen (Hansen 2013) describes a neuropilin1/
VEGF – mediated trafficking of Tregs as a prerequisite for
tumor infiltration. Our study suggests a potential correl-
ation between serum VEGF expression and T reg expan-
sion in peripheral blood in melanoma patients. Ongoing
investigation is needed to fully elucidate the role of VEGF
in regulatory T cell functions.
LDH was the only baseline parameter to correlate with
survival. Our model found that baseline LDH was pre-
dictive of survival in stage IV patients, which means that
with each one-unit increase in LDH, estimated mortality
risk increases by 0.17% and for a 100-unit increase in
LDH, estimated mortality risk increases by 18.5%. In our
study patients with higher LDH levels have higher VEGF
levels, an association which has been previously reportedby Sabatino et al. (Sabatino et al. 2009). In this prior re-
port, elevations of VEGF were associated with signifi-
cantly reduced overall survival (Sabatino et al. 2009).
Our preliminary observations may warrant a larger pro-
spective study examining LDH and serum VEGF levels
in patients being considered for high-dose IL-2 therapy.
Elevation of VEGF and reduced overall survival did not
reach statistical significance in our study. However, there
was a trend toward significance. For stage IV patients
the correlation between survival at stage from diagnosis
and baseline VEGF was −0.375 (p-value = 0.085). There-
fore, baseline VEGF and survival were negatively correlated.
If our study population were larger, this observation may
have reached statistical significance. These baseline serum
(LDH and VEGF) and cellular (Treg and Th1/Th2)
parameters are worthy of further study in new treatment
paradigms, which are rapidly developing with the era of
new immunotherapies. Tumor biopsies prior to and during
treatment are crucial to investigate local changes around
the tumor milieu with ipilimumab and anti-PD1 therapies,
especially with regard to Treg around tumor. Systemic
Treg and tumor Treg may not necessarily correlate except
for extreme cases, and the local effect within the tumor
microenvironment is likely to be of greater importance
than systemic Treg levels. Study of these crucial parameters
may help us define the optimal options to achieve best
survival. At present, studies are ongoing or initiating
combining IL-2 with anti-PD1, ipilimumab with anti-
PD1, sequential IL-2/ipilimumab/anti-PD-1, sequential
ipilimumab/anti-PD1, among others. This may establish
Agostino et al. SpringerPlus  (2015) 4:186 Page 8 of 9treatment paradigms, based on baseline immune status
and angiogenesis activation, that are more efficacious and
cost-effective.
There are several limitations to our study which need
to be mentioned. First, we used a convenience sampling
method as opposed to a random sampling method. Sec-
ond, both newly diagnosed stage IV melanoma patients
and exceptional survivors of stage IV melanoma, many
who had received past immunotherapy treatments, were
included. Therefore, it is possible that our sample may
not accurately represent the larger population of all
stage III and IV melanoma patients as is reflected in our
exceptionally long overall survival. Nevertheless, exam-
ining T-cell characteristics of metastatic melanoma pa-
tients, including exceptional melanoma survivors, may
gain us further insight into underlying immunomodula-
tion mechanisms that may help guide improved therap-
ies. An additional limitation of our study is the small
sample size, which limited our ability to collect and con-
trol for confounding factors in the regression analysis.
The prospective collection of data contributes to the
strength of our study, as it ensures the accuracy of the
observations. Future prospective studies, with larger sam-
ple sizes, are needed to further validate our observations.
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